Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Core Insights - Crescent Biopharma has established a partnership with Kelun-Biotech to expand its oncology pipeline and accelerate its combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs) [1][5] - The ASCEND Phase 1/2 global clinical trial for CR-001 is currently underway, with three additional clinical trials expected to initiate in 2026 [1][2] - The company completed a $185 million private placement, which will support key clinical data readouts starting in Q1 2027 and provide a cash runway into 2028 [1][9] Business Highlights - The partnership with Kelun-Biotech allows Crescent to leverage exclusive rights for CR-001 in Greater China while obtaining rights for CR-003 in the U.S. and Europe [5] - Crescent's CEO highlighted the transformative nature of 2025 for the company, emphasizing the advancement of next-generation therapies and the ongoing ASCEND trial for CR-001 [2] - The company anticipates proof-of-concept clinical data from the ASCEND trial in Q1 2027, including initial safety and preliminary antitumor activity [5][6] Financial Performance - As of December 31, 2025, Crescent reported cash and cash equivalents of $213.2 million, expected to fund operations into 2028 [9] - The company generated revenue of $10.8 million for the year ended December 31, 2025, attributed to a $20 million upfront payment from Kelun-Biotech [9] - Research and development expenses increased significantly to $138.1 million for the year, driven by the development of CR-001 and CR-002, along with an $80 million upfront payment to Kelun-Biotech for CR-003 [10] Pipeline Developments - CR-001 is positioned as a potential immuno-oncology backbone for treating solid tumors, with ongoing trials evaluating its efficacy in various cancer types [2][5] - Crescent plans to initiate a Phase 1/2 trial for CR-002 in mid-2026, with proof-of-concept data expected in the second half of 2027 [14] - CR-003 has received IND approval in China, with a Phase 1/2 trial expected to start in Q1 2026 [14]